Abstract: An oral composition includes an immediate-release pharmaceutical admixture and an extended-release pharmaceutical admixture. The immediate-release pharmaceutical admixture includes a first portion of an active ingredient and a first portion of a hydrophilic dispersant, in which the active ingredient is substantially insoluble in water. The extended-release pharmaceutical admixture includes a controlled-release material, a second portion of the active ingredient, and a second portion of the hydrophilic dispersant, wherein the second portion of the active ingredient and the second portion of the hydrophilic dispersant are mixed in the controlled-release material, wherein the active ingredient is present as a nanoparticle in the immediate-release pharmaceutical admixture and the extended-release pharmaceutical admixture.

Abstract: A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.

Abstract: An oral composition includes an immediate-release pharmaceutical admixture and an extended-release pharmaceutical admixture. The immediate-release pharmaceutical admixture includes a first portion of an active ingredient and a first portion of a hydrophilic dispersant, in which the active ingredient is substantially insoluble in water. The extended-release pharmaceutical admixture includes a controlled-release material, a second portion of the active ingredient, and a second portion of the hydrophilic dispersant, wherein the second portion of the active ingredient and the second portion of the hydrophilic dispersant are mixed in the controlled-release material, wherein the active ingredient is present as a nanoparticle in the immediate-release pharmaceutical admixture and the extended-release pharmaceutical admixture.

Abstract: A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.

Abstract: A gate driving circuit is provided. The gate driving circuit includes multistage driving modules, where an Nth stage driving module includes a setting circuit, a first driving circuit, an isolating switch circuit, a second driving circuit and an anti-noise circuit. The setting circuit generates a first precharge signal according to a gate driving signal of an (N?2)th scan line or a start signal. The isolating switch circuit coupled between the first driving circuit and the second driving circuit provides a second precharge signal, so as to effectively avoid a flickering problem of a display image caused by a surge of the gate driving signal due to a coupling effect of a parasitic capacitance of the transistor and a bootstrap capacitor, and meanwhile the bootstrap capacitor is not used, so as to effectively reduce a bezel area.

Abstract: A gate driving circuit is provided. The gate driving circuit includes multistage driving modules, where an Nth stage driving module includes a setting circuit, a first driving circuit, an isolating switch circuit, a second driving circuit and an anti-noise circuit. The setting circuit generates a first precharge signal according to a gate driving signal of an (N?2)th scan line or a start signal. The isolating switch circuit coupled between the first driving circuit and the second driving circuit provides a second precharge signal, so as to effectively avoid a flickering problem of a display image caused by a surge of the gate driving signal due to a coupling effect of a parasitic capacitance of the transistor and a bootstrap capacitor, and meanwhile the bootstrap capacitor is not used, so as to effectively reduce a bezel area.

Abstract: A touch sensing three-dimensional (3D) display device includes a display panel and a touch sensing parallax integrated panel. The touch sensing parallax integrated panel located on the display panel includes a first substrate, a second substrate, a touch sensing structure, a display medium layer, a first parallax electrode layer, and a second parallax electrode layer. The second substrate is disposed opposite to the first substrate. The first substrate is located between the display panel and the second substrate. The touch sensing structure is located on the second substrate. The display medium layer is disposed between the first substrate and the second substrate. The first parallax electrode layer disposed on the first substrate is located between the display medium layer and the first substrate. The second parallax electrode layer disposed on the second substrate is located between the display medium layer and the second substrate.

Abstract: A sensing structure of a touch panel includes a substrate, a plurality of sensing electrodes, a plurality of electro static discharge (ESD) protection electrodes, a plurality of first bridges, and a passivation layer. The sensing electrodes, the ESD protection electrodes, and the first bridges are disposed on the substrate. The passivation layer is disposed between the sensing electrode and the first bridge, and disposed between the ESD protection electrode and the first bridge. The passivation layer has a plurality of contact holes, and at least one sensing electrode is electrically connected to the ESD protection electrode via the contact hole and the first bridge.

Abstract: A method of preparing a taste-masking oral dosage form is provided. The method includes providing a first solution comprising a pharmaceutically active ingredient and a starch, providing a second solution comprising a hydrophilic polymer and a surfactant, blending the first and second solution to form a plurality of microparticles by a granulating process, wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch, and performing a compression-molding process to form the tablet.

Abstract: A sensing structure of a touch panel includes a substrate, a plurality of sensing electrodes, a plurality of electro static discharge (ESD) protection electrodes, a plurality of first bridges, and a passivation layer. The sensing electrodes, the ESD protection electrodes, and the first bridges are disposed on the substrate. The passivation layer is disposed between the sensing electrode and the first bridge, and disposed between the ESD protection electrode and the first bridge. The passivation layer has a plurality of contact holes, and at least one sensing electrode is electrically connected to the ESD protection electrode via the contact hole and the first bridge.

Abstract: The present invention provides a method for making a fast dissolving tablet. The method includes the steps of (a) preparing a first solution containing a hydrophilic polymer and a starch; (b) preparing a second solution containing a pharmaceutically active ingredient and a surfactant; (c) blending the first and the second solution together to form a plurality of granule powders by granulation; (d) mixing the granule powders with excipients; and (e) applying a compression-molding process to form the fast dissolving tablet.

Abstract: The present invention provides a taste-masking oral dosage form which comprises a taste-masked microparticle and an excipient. The taste-masked microparticle comprises a taste-masked crystal containing an active pharmaceutical ingredient masked by a hydrophilic polymer and a starch. The present invention also provides a method for making the taste-masked microparticles and taste-masking oral dosage form.

Abstract: A taste-masking oral dosage form. The taste-masking oral dosage form comprises a pharmaceutically active ingredient, and a starch, wherein the pharmaceutically active ingredient is packaged by the starch to form a microparticle. A method of preparing the taste-masking oral dosage form is also disclosed.

Abstract: A fast dissolving tablet. The fast dissolving tablet comprises a pharmaceutically active ingredient, a starch, a hydrophilic polymer, a surfactant, and excipients. A method of preparing the fast dissolving tablet is also disclosed.

Abstract: A taste-masking oral dosage form. The taste-masking oral dosage form comprises a pharmaceutically active ingredient, and a starch, wherein the pharmaceutically active ingredient is packaged by the starch to form a microparticle. A method of preparing the taste-masking oral dosage form is also disclosed.

Abstract: The present invention provides a fast-disintegrating tablet (RDT) and the method of preparing the RDT. The RDT contains a plurality of microcapsules which contains an active pharmaceutical ingredient surrounded by a polymeric matrix formed by a hydrogel. The microcapsules are separated from each other by a surfactant, particularly lecithin. The RDT is particularly suitable for use as a drug delivery system for antiacid or antiulcer drugs, such as famotidine. The RDT is further characterized by their its fast disintegration time of about 3 second to 3 minutes.